TERMINAL
HEALTHCARE2/27/2026 • LIVE

Novo Nordisk A/S (NVO)

Novo Nordisk A/S (NVO) is a healthcare company operating in drug manufacturers—general. Valuation and momentum can move with trial outcomes, regulatory news, and reimbursement shifts. Use this profile to monitor momentum shifts, volatility regime, and valuation signals in one dashboard.

PRICE
$37.62
-1.42% today
RISK
VERY HIGH

Key Metrics

MARKET CAP
$167.22B
P/E RATIO
10.3
BETA
0.40
Less volatile
DIV YIELD
4.94%
52W HIGH
$91.90
52W LOW
$37.31
VOLATILITY
87.2%
30d annualized

Price Performance

30-DAY PRICE CHART

$62.89 → $37.62-40.18%
30 days agoToday

1-YEAR PERFORMANCE

$90.65 → $37.62-58.5%
$51$65$80FebMarAprMayJunJulAugSepOctNovDecJan
NVO | 52-week chartLast updated: 2/27/2026

Healthcare Sector Context

Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.

METRICNVOSECTOR AVGVS SECTOR
P/E Ratio10.3x22.0x↓ 53%
Beta0.400.85Less volatile
Div Yield4.94%1.50%Above avg
30d Volatility87.2%22%Higher risk

TOP HEALTHCARE PEERS

UNHJNJPFE

Competitors Analysis

Compare NVO's key metrics against its main healthcare sector competitors.

COMPANYPRICEMARKET CAPSECTOR
NVO(You are here)
$37.62$167.22BHealthcare—
UNH$286.66$259.67BHealthcareVIEW →
JNJ$243.47$586.74BHealthcareVIEW →
PFE$27.10$154.08BHealthcareVIEW →
Click on a competitor to view their full analysis

Technical Analysis

Novo Nordisk A/S is currently trading at $37.62, which is 59.1% below its 52-week high. With a beta of 0.40, the stock shows lower sensitivity to market movements.

RSI (14)OVERSOLD
30-DAY TRENDBEARISH
VOLUME34.8M(Above avg)

Frequently Asked Questions

Is NVO a good buy right now?

Novo Nordisk A/S trades at 10.3x earnings. This is below market average, potentially undervalued. Current risk level is Very High based on 87.2% volatility.

Does NVO pay dividends?

Yes, Novo Nordisk A/S offers a dividend yield of 4.94%. This translates to approximately $1.86 per share annually.

How volatile is NVO?

With 30-day annualized volatility of 87.2% and beta of 0.40,NVO is classified as Very High risk. The stock tends to be more stable than the market average.

Related Assets

LLYANALYZE →
Eli Lilly and Company
UNHANALYZE →
UnitedHealth Group
JNJANALYZE →
Johnson & Johnson
ABBVANALYZE →
AbbVie Inc.
MRKANALYZE →
Merck & Co.

Track NVO Live

Add Novo Nordisk A/S to your Portfolio Terminal for real-time alerts and risk updates.

OPEN TERMINAL
Last updated: 2/27/2026, 2:03:32 PM